Evercore ISI Group Rates Inspire Medical Systems (INSP) hold

Evercore ISI Group has downgraded Inspire Medical Systems to a 'hold' rating with a $40 price target, a 7.94% downside from the current price.

By EarningsIQ Research Desk · Published Jun 26, 2026, 3:03 AM EDT · Updated Jun 26, 2026, 8:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Evercore ISI Group rated Inspire Medical Systems, Inc. ($INSP) "hold" with a $40 price target on June 23, 2026.

Since the rating, $INSP is up 6.8% after 1 week, up 21.7% after 1 month and up 64.8% to date (from the $41.75 close on Jun 23, 2026).

INSP Inspire Medical Systems, Inc.

$68.79 -25.45% year to date

Daily close · Oct 16, 2026

Key Points

Evercore ISI Group downgraded Inspire Medical Systems to a 'hold' rating with a $40 price target on June 23, 2026.
Evercore ISI Group's $40 price target implies 7.94% downside from Inspire Medical Systems, Inc.'s ($INSP) current $43.45 share price.
Inspire Medical Systems, trading at $43.20 on Friday, has a market cap of $1.25 billion and a P/E ratio of 9.88.
Insider John Rondoni sold shares on multiple occasions in May 2026, while analyst consensus remains at 'hold' with a target mean price of $50.92.

Get $INSP trade alerts by text

We text you when insiders, Congress or big funds trade $INSP. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Inspire Medical Systems, Inc. alert may contain errors. Disclosures

Evercore ISI Group has made a significant move by downgrading Inspire Medical Systems, Inc. (NYSE:INSP) to a 'hold' rating, setting a new price target of $40. This change, announced on June 23, 2026, comes as part of the firm's reassessment of the company's prospects.

Analyst rating track record

Evercore ISI Group vs. the S&P 500

YTD return +12.75% hypothetical

All-time return +25.67% S&P 500 +26.33%

vs. S&P 500 -0.66% behind the index

Hypothetical returns from Evercore ISI Group's disclosed trades, not real profit or advice. How we model this.

Inspire Medical Systems, Inc. Stock Down 43.4%

Shares of NYSE:INSP traded at $43.20 on Friday. Inspire Medical Systems has a market capitalization of approximately $1.25 billion. The company's P/E ratio is 9.88, with a forward P/E of 33.60 and a beta of 0.73. Over the past 52 weeks, the stock has ranged from a low of $38.91 to a high of $147.03. Its 50-day moving average is $46.24, while the 200-day moving average stands at $72.32. The company also maintains a strong current ratio of 6.34 and a quick ratio of 4.35, with a debt-to-equity ratio of 3.73.

12-month forecast

$INSP price target

Inspire Medical Systems, Inc. daily closes and this analyst's $40 target. Not advice.

Recent Earnings

Inspire Medical Systems reported revenue of $915.25 million, with a modest growth rate of 1.6%. The company's net margin is 14.33%, and it achieved a return on equity of 18.37%. The next earnings report is expected on August 3, 2026.

Insider Buying and Selling at Inspire Medical Systems, Inc.

In May 2026, John Rondoni, the Chief Product and Innovation Officer, sold 2,641 shares on May 15 at an average price of $43.28, and an additional 700 shares on May 14 at $43.01. Meanwhile, insider transactions also included planned sales by Shawn McCormick and Georgia Melenikiotou, as well as purchases by Gary Lee Ellis and Cynthia Burks on April 30.

Analysts Set New Price Targets

On June 23, 2026, Evercore ISI Group downgraded Inspire Medical Systems to a 'hold' rating with a $40 price target. Other analysts, such as JP Morgan and Piper Sandler, recently maintained or downgraded the stock to similar ratings, with price targets ranging from $45 to $65. The consensus among 12 analysts is a 'hold' recommendation, with a target mean price of $50.92.

About Inspire Medical Systems

Inspire Medical Systems, Inc. is a healthcare company based in Golden Valley, Minnesota. It specializes in developing and selling minimally invasive medical devices for treating obstructive sleep apnea (OSA). The company's flagship product, the Inspire system, uses neurostimulation technology to help maintain an open airway during sleep. Founded in 2007, the company is led by CEO Timothy P. Herbert and employs around 1,333 people.

Bottom Line

The downgrade by Evercore ISI reflects a cautious stance on Inspire Medical Systems, as the new price target suggests limited upside from current levels. Investors often track these ratings for insights into market sentiment and potential stock movements. Remember, analyst ratings are opinions and should be considered alongside other factors in investment decisions.